Gday HurleyThere are only about 15 people that post on the EMS...

Gday Hurley

There are only about 15 people that post on the EMS thread so I wouldn’t classify their thoughts as “a lot of people”

But FWIW yes Artimist would be on the radar of many in the drug/pharma industry. It was listed by Reuters as one of the 5 most promising drugs in the world, and a few months ago I posted a chart which showed every single malaria product and its phase of clinical development.

Artimist is one of the very few in Phase III trial land (and of course now has completed patient dosing), and furthermore, it would probably be the most developed malaria treatment product focusing on children.

Where this conference could be of benefit is increasing the visibility of the Artimist project to the UN, government representatives and the NGO sector. Not to mention one of the great donors in this field, the Bill and Melinda Gates Foundation, are also co-sponsoring the event.

This is largely a political conference and I am not expecting many companies to be invited. Eastland, with its Phase III treatment is perfectly positioned as it’s a late stage clinical product with proven benefits compared with existing treatment.

The increase in visibility for the product among this important audience is a potentially very positive event.

Does it mean the share price will rise 20% following the conference? Who knows. I doubt it. It does depend on whether the EMS CEO has many/any 1:1 meetings planned, or whether he will be there to network (in addition to the poster presentations)
But if there is a positive press release from the company regarding the outcomes of some important 1:1 meetings then who knows how the market will respond.

Regardless of the conference results, we are fast approaching the time when the results of the trial will be released, and as I have said many times before… a market cap of $20m for a company with its lead product having completed patient dosing for a Phase III multi-centre trial based on an existing and approved product using a delivery system that is shown to not only have higher absorption rates but is easier to administer does not accurately reflect the true worth of where the company is at in its commercialization plan.

Good luck